Raymond James Financial
AARD

Raymond James Financial’s Aardvark Therapeutics AARD Stock Holding History

Raymond James Financial’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457K Buy
79,284
+68,394
+628% +$320K ﹤0.01% 4571
2026
Q1 		$41.1K Buy
+10,890
New +$113K ﹤0.01% 5142

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Raymond James Financial's AARD Position: Q2 2026 in Review

Raymond James Financial increased its Aardvark Therapeutics (AARD) stake by 628% in Q2 2026, buying an estimated $320K and bringing the position to 79,284 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #4571.

Raymond James Financial first reported a position in AARD in Q1 2026 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Raymond James Financial held 79,284 shares of Aardvark Therapeutics worth $457K as of Q2 2026.
  • Raymond James Financial bought 68,394 Aardvark Therapeutics shares in Q2 2026, an estimated $320K.
  • Aardvark Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4571 holding.
  • Raymond James Financial first reported a position in Aardvark Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.